KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2020 - 2025)

Aurinia Pharmaceuticals' Cash from Financing Activities history spans 6 years, with the latest figure at -$1.9 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 91.8% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$106.1 million, down 116.15%, while the annual FY2025 figure was -$106.1 million, 116.15% down from the prior year.
  • Cash from Financing Activities reached -$1.9 million in Q4 2025 per AUPH's latest filing, up from -$10.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $205.7 million in Q4 2021 to a low of -$49.3 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $3.3 million, with a median of -$1.9 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: soared 304.69% in 2023, then plummeted 1018.3% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $205.7 million in 2021, then crashed by 99.67% to $688000.0 in 2022, then plummeted by 910.61% to -$5.6 million in 2023, then plummeted by 313.23% to -$23.0 million in 2024, then skyrocketed by 91.8% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Cash from Financing Activities are -$1.9 million (Q4 2025), -$10.5 million (Q3 2025), and -$44.4 million (Q2 2025).